Chronic Obstructive Pulmonary Disease Market Report by DelveInsight

DelveInsight's Chronic Obstructive Pulmonary Disease (COPD) Market report puts forward a detailed perspective on epidemiology, current treatment practices, emerging drugs, COPD market share of the individual therapies, current and forecasted Chronic Obstructive Pulmonary Disease market size for the study period 2018 to 2030 spanning across 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Key highlights from the Chronic Obstructive Pulmonary Disease Market report: 

• Key pharma companies actively pushing the pace of drug development in the Chronic Obstructive Pulmonary Disease market include Afimmune, Allakos, Amgen/AstraZeneca, Arrowhead Pharmaceuticals, Astellas Pharma, AstraZeneca, Boehringer-Ingelheim, Brickell Biotech, Chiesi Farmaceutici S.p.A., Chiesi USA, Inc., Dimerix, EpiEndo Pharmaceuticals, Genentech, GlaxoSmithkline, GSNOR Therapeutics, InMed Pharmaceuticals, Ionis Pharmaceuticals, KeyMed Biosciences, Laboratoires SMB, Mereo BioPharma, Meridigen Biotech, Nephron Pharmaceuticals, Novartis, Pulmatrix Inc., Pulmotect, Quercegen Pharmaceuticals, Regend Therapeutics, Regeneron Pharmaceuticals/Sanofi, Sulfateq BV, Synairgen, Tetherex Pharmaceuticals, Verona Pharma, Vertex Pharmaceuticals, and several others. 
• The two biologics in the COPD pipeline, GSK's Nucala (mepolizumab) and AstraZeneca's Benralizumab, are the only therapies offering a novel mechanism of action. 
• The approved bronchodilators for the treatment of COPD include Stiolto Respimat (Boehringer Ingelheim), Spiriva Respimat and Spiriva Handihaler (Boehringer Ingelheim), Striverdi Respimat (Boehringer Ingelheim), Incruse Ellipta (GlaxoSmithKline), Tudorza Pressair (Forest Laboratories), Yupelri (Theravance Biopharma).

Download Sample report to understand which drug is going to nab the maximum market share @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market

View Report: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market

Chronic Obstructive Pulmonary Disease: Overview

Chronic Obstructive Pulmonary Disease is a major health problem characterized by progressive airflow limitation and tissue destruction. It is majorly of two types: Chronic Bronchitis and Emphysema. Chronic bronchitis results in inflammation and irritation of the airways making the lining of the airways thick, whereas Emphysema damages the walls of the alveolar sacs reducing the amount of gas exchange in the lungs. 

With the advances in every field such as medical technology, awareness of the disease, huge strides of improvements have been taken in properly mapping the COPD epidemiology, clinical features and presentation, associated comorbidities, and treatment. 

Chronic Obstructive Pulmonary Disease Epidemiology

Chronic Obstructive Pulmonary Disease is currently the third most common cause of global morbidity and mortality. As per COPD epidemiological analysis, COPD is primarily present in smokers, especially in the age group >40 years. The COPD prevalence increases with the age, however, the prevalence is most likely underestimated owing to the underdiagnosis of COPD.

Chronic Obstructive Pulmonary Disease Market Insights Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into:

• Total Chronic Obstructive Pulmonary Disease prevalent cases 
• Total age-specific diagnosed COPD prevalent cases
• Total gender-specific diagnosed COPD prevalent cases 
• Total subtype-specific diagnosed COPD prevalent cases
• Total COPD treatable and diagnosed cases 
• Total severity-specific diagnosed COPD prevalent cases

View Report: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market

Visit for deep insights into Chronic Obstructive Pulmonary Disease patient pool @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market

Chronic Obstructive Pulmonary Disease Therapy Market 

The primary goal of COPD treatment remains alleviating symptoms and addressing exacerbations, reducing mortality rate, and altering the underlying nature of the disease (otherwise known as 'disease modification').

Currently, there are 9 approved drug categories for COPD maintenance medication. However, the majority of these available treatment options are largely iterations of bronchodilators, which open airways and but no pharmacological treatment has the potential to prevent the progression of lung destruction. The only way to stop the disease from getting worse is to stop smoking. 

View Report: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market

Check out for more @ Chronic Obstructive Pulmonary Disease Market Forecast

COPD Available Therapies and Treatment Options 

• Bronchodilators
• Short-Acting Beta-2 Agonists
• Long-Acting Beta-2 Agonists
• Anticholinergic Agents
• Anti-inflammatory Drugs
• Oral and Inhaled Corticosteroids
• Anti-leukotrienes
• Phosphodiesterase Type-4 Inhibitors
• Other Anti-inflammatory Drugs
• Monoclonal Antibodies
• Combination Drugs

Chronic Obstructive Pulmonary Disease Market

The Chronic Obstructive Pulmonary Disease market is expected to swell up owing to the major traction of the pharma companies investing in the domain, awareness, healthcare funding, and novel therapeutic advances. More than 60 therapies are in different stages of development. Major players such as Afimmune, Inmunotek S.L., Sanofi, Regeneron, Pulmotect, Verona Pharma, and several others are investigating their therapies in the late-stage trials and continually working to strengthen the COPD drug pipeline. 

Inmunotek S.L. is investigating its MV130, a bacterial mucosal vaccine spray, stimulates dendritic cells to modulate the functional activity of the innate and adaptive immune response. The company is currently conducting a Phase III trial to evaluate the efficacy and safety of MV130 in patients with COPD. 

The duo, Sanofi/Regeneron, is targeting two key proteins that are thought to play a central role in type 2 inflammation. The companies are investigating a fully human monoclonal antibody, SAR440340, that inhibits interleukin-33 (IL-33), and a targeted biologic therapy, Dupilumab, that along with inhibiting signaling of interleukin-13 (IL-13) also inhibits interleukin-4 (IL-4) signaling. Both the agents are in the Phase III trial for the treatment of COPD. 

Another clinical-stage biopharma, Verona Pharma is investigating Ensifentrine (RPL554), an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 ("PDE3" and "PDE4") in the Phase III clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment. 

View Report: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market

Key Pharma Companies in the Chronic Obstructive Pulmonary Disease Market

• Afimmune
• Allakos
• Amgen/AstraZeneca
• Arrowhead Pharmaceuticals
• Astellas Pharma
• AstraZeneca
• Boehringer-Ingelheim
• Brickell Biotech
• Chiesi Farmaceutici S.p.A.
• CHIESI USA, Inc.
• Dimerix
• EpiEndo Pharmaceuticals
• Genentech
• GlaxoSmithKline
• GSNOR Therapeutics
• InMed Pharmaceuticals
• Ionis Pharmaceuticals
• KeyMed Biosciences
• Laboratoires SMB
• Mereo BioPharma
• Meridigen Biotech
• Nephron Pharmaceuticals
• Novartis
• Pulmatrix Inc.
• Pulmotect
• Quercegen Pharmaceuticals
• Regend Therapeutics
• Regeneron Pharmaceuticals/Sanofi
• Sulfateq BV
• Synairgen
• Tetherex Pharmaceuticals
• Verona Pharma
• Vertex Pharmaceuticals
• Yungjin Pharm. Co., Ltd.

Chronic Obstructive Pulmonary Disease Market Drivers and Barriers 

All of the available drugs and therapies in the COPD therapy market are symptomatic in nature. In the last decade, only one drug has entered the COPD market. However, a better understanding of the disease and its pathophysiology has surged the development of therapies in the COPD market. Besides, a growing prevalence and an aging population are also pushing the market growth. 

Novel investigational products in development targeting immune mediators are expected to show promising results on this front. The updated diagnosis paradigm, validation, and approval of patient-reported outcome questionnaires for clinical trials, and drug development tools, such as a prognostic biomarker for patient selection have further helped in stepping up the therapeutic approaches that are efficient, safe, and effective. 

Lastly, the increasing number of government initiatives along with nongovernment organizations have successfully managed to bring a lot of awareness around pollution and smoking that are major causes of COPD, thereby, impacting lifestyle in a positive manner and increase adoption of the drugs for treatment, ultimately, leading to vertical growth.